首页> 外国专利> Humanized antibody specific for TSLP (thymic stromal lymphopoietin) and Pharmaceutical compositions

Humanized antibody specific for TSLP (thymic stromal lymphopoietin) and Pharmaceutical compositions

机译:对TSLP(胸腺基质淋巴细胞生成素)和药物组合物具有特异性的人源化抗体

摘要

Refers to a Humanized Antibody to isolated or a functional fragment comprising an Antigen binding region that is specific to TSLP (thymic stromal lifopoyetina human) with a KD of 1x10 - 9 m or less.Said Antibody comprises: (a) a region (SEQ ID no: CDR1 selected 38, a selected region L - CDR2 of SEQ ID no: 47, a L - Selected CDr3 region of SEQ ID no: 60; (b) a selected region (SEQ ID no: CDR1 Region 3, H - CDR2 selected seq id: SEQ ID: 15, 17, 18, SEQ ID: SEQ ID : 19SEQ ID: 20 and CDR3 Region H - Selected SEQ ID: 28 and Conservative variants of the same. Also referred to a Pharmaceutical composition with pharmaceutically acceptable excipients. This Antibody is useful in the treatment of diseases such as Asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma
机译:指人源化抗体,其分离的或功能片段包含对TSLP(胸腺间质脂溶性眼膜炎人)具有特异性的KD为1x10-9 m或更小的抗原结合区。所说的抗体包括:(a)一个区域(SEQ ID否:选择的CDR1 38,SEQ ID No:47的选定区域L-CDR2,SEQ ID No:60的L-选定的CDr3区;(b)选定的区域(SEQ ID No:CDR1的区域3,H-CDR2选定的seq id:SEQ ID:15、17、18,SEQ ID:SEQ ID:19,SEQ ID:20和CDR3区H-选择的SEQ ID:28和其保守变体,也指具有药学上可接受的赋形剂的药物组合物该抗体可用于治疗哮喘,特应性皮炎,过敏性鼻炎,纤维化,炎症性肠病和霍奇金淋巴瘤等疾病

著录项

  • 公开/公告号PE01122008A1

    专利类型

  • 公开/公告日2008-03-13

    原文格式PDF

  • 申请/专利权人 NOVARTIS AG;

    申请/专利号PE20070000198

  • 申请日2007-02-22

  • 分类号A61K39/395;C07K16/18;C07K16/24;

  • 国家 PE

  • 入库时间 2022-08-21 20:06:37

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号